azd2693
Nucleic acidexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 28, 2019 (NCT04142424)
Timeline
Indications
Mechanism of action
- 1-acylglycerol-3-phosphate O-acyltransferase PNPLA3Supplementation
PNPLA3 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05919069 | Phase 1 | Jun 16, 2023 | AstraZeneca |
| NCT05809934 | Phase 2 | Mar 15, 2023 | AstraZeneca |
| NCT05107336 | Phase 1 | Nov 15, 2021 | AstraZeneca |
| NCT04483947 | Phase 1 | Nov 6, 2020 | AstraZeneca, Parexel, University of California, San Diego |
| NCT04142424 | Phase 1 | Oct 28, 2019 | AstraZeneca, Parexel |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 5 | 5 | 2 | 2019 |
| Parexel | For profit | 2 | 0 | 1 | 2019 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1